A5032907896- Bone health and osteoporosis research
- Bone health and treatments
- Bone Metabolism and Diseases
- Bone and Joint Diseases
- Hip and Femur Fractures
- Vitamin D Research Studies
- Bone fractures and treatments
- Cancer Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Medical Imaging and Pathology Studies
- Pelvic and Acetabular Injuries
- Orthopaedic implants and arthroplasty
- Hip disorders and treatments
- Fibroblast Growth Factor Research
- Bone Tumor Diagnosis and Treatments
- Estrogen and related hormone effects
- Rheumatoid Arthritis Research and Therapies
- Cardiac, Anesthesia and Surgical Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Medical Imaging and Analysis
- Cancer and Skin Lesions
- Oral health in cancer treatment
- Synthesis and Reactions of Organic Compounds
- Inflammatory mediators and NSAID effects
- Osteomyelitis and Bone Disorders Research
Université Laval
2016-2025
Centre hospitalier universitaire de Québec
2009-2024
Wilfrid Laurier University
2018-2024
Quebec Research and Development Centre
2013-2022
Centre hospitalier de l'Université Laval
2010-2021
University of Maryland, Baltimore
1971-2018
Milton District Hospital
2017
Osteoporosis Canada
2005-2013
University of Saskatchewan
2007-2009
University of Calgary
2009
ContextRisedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Paget disease bone and other metabolic diseases but, our knowledge, it not evaluated established postmenopausal osteoporosis.ObjectiveTo test efficacy safety daily with risedronate reduce risk vertebral fractures women osteoporosis.Design, Setting, ParticipantsRandomized, double-blind, placebo-controlled trial 2458 ambulatory younger than 85 years at least 1 fracture baseline who were enrolled 110...
See related commentary by Kanis, page [1829][1] Since the publication of Osteoporosis Canada guidelines in 2002, there has been a paradigm shift prevention and treatment osteoporosis fractures. [1][2],[2][3] The focus now is on preventing fragility fractures their negative
Osteoporosis is a common complication of long-term glucocorticoid therapy for which there no well-proved preventive or restorative treatment.
Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation.In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy safety over 12-month period in 419 postmenopausal women, 55 85 years age, who had low mineral density (a T score -2.0 or less at lumbar spine, total hip, femoral neck -3.5 more each three sites)....
Systemic corticosteroids play an integral role in the management of many inflammatory and immunologic conditions, but these agents are also associated with serious risks. Osteoporosis, adrenal suppression, hyperglycemia, dyslipidemia, cardiovascular disease, Cushing's syndrome, psychiatric disturbances immunosuppression among more side effects noted systemic corticosteroid therapy, particularly when used at high doses for prolonged periods. This comprehensive article reviews adverse events...
Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, optimal doses dosing interval not systematically explored.
Osteoporosis is a recognized complication of corticosteroid therapy. Whether it can be prevented not known. We conducted 12-month, randomized, placebo-controlled study intermittent etidronate (400 mg per day for 14 days) followed by calcium (500 76 days), given four cycles, in 141 men and women (age, 19 to 87 years) who had recently begun high-dose The primary outcome measure was the difference change bone density lumbar spine between groups from base line week 52. Secondary measures...
ABSTRACT Denosumab reduces bone resorption and vertebral nonvertebral fracture risk. discontinuation increases turnover markers 3 months after a scheduled dose is omitted, reaching above-baseline levels by 6 months, decreases mineral density (BMD) to baseline 12 months. We analyzed the risk of new or worsening fractures, especially multiple in participants who discontinued denosumab during FREEDOM study its Extension. Participants received ≥2 doses placebo Q6M, treatment, stayed ≥7 last...
Denosumab is a fully human monoclonal antibody that inhibits bone resorption by neutralizing RANKL, key mediator of osteoclast formation, function, and survival. This phase 3, multicenter, doubleblind study compared the efficacy safety denosumab with alendronate in postmenopausal women low mass. One thousand one hundred eighty-nine T-score <or= -2.0 at lumbar spine or total hip were randomized 1:1 to receive subcutaneous injections (60 mg every 6 mo [Q6M]) plus oral placebo weekly (n = 594)...
To evaluate the continued efficacy and safety of alendronate (ALN) for up to 2 years in patients receiving glucocorticoids.This is a 12-month extension previously completed 1-year trial daily ALN, performed effects ALN over total 66 men 142 women continuing receive at least 7.5 mg prednisone or equivalent daily. All received supplemental calcium vitamin D. The primary end point was mean percentage change lumbar spine bone mineral density (BMD) from baseline 24 months. Other outcomes included...
Patients treated with bisphosphonates for osteoporosis may discontinue or require a switch to other therapies. Denosumab binds RANKL and is potent inhibitor of bone resorption that has been shown increase mineral density (BMD) decrease fracture risk in postmenopausal women osteoporosis. This was multicenter, international, randomized, double-blind, double-dummy study 504 > = 55 years age BMD T-score -2.0 less -4.0 more who had receiving alendronate therapy at least 6 months. Subjects...
The advent of bisphosphonates advanced therapy for Paget's disease, but more effective and convenient agents are needed to increase adherence. Zoledronic acid, a bisphosphonate administered as single intravenous infusion, might meet these needs.
<b>Background:</b> Fractures have largely been assessed by their impact on quality of life or health care costs. We conducted this study to evaluate the relation between fractures and mortality. <b>Methods:</b> A total 7753 randomly selected people (2187 men 5566 women) aged 50 years older from across Canada participated in a 5-year observational cohort study. Incident were identified basis validated self-report classified type (vertebral, pelvic, forearm wrist, rib, hip "other"). subdivided...
Abstract The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for treatment postmenopausal women with osteoporosis. Participants who completed were eligible to enter an extension continue evaluation up 10 years. For results presented here, from group had 2 more years (long-term group) those placebo exposure (cross-over group). We report bone turnover markers (BTMs), mineral density (BMD), fracture rates, safety. A total 4550 enrolled in (2343 long-term;...
The Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) extension is evaluating the long-term efficacy and safety denosumab for up to 10 years.The objective study was report results from first 3 years extension, representing exposure.This a multicenter, international, open-label 4550 women.Women FREEDOM group received more total (long-term) women placebo (crossover).Bone turnover markers (BTMs), bone mineral density (BMD), fracture, data are...